{"product_id":"stage-iv-breast-cancer-during-pregnancy-or-after-childbirth-what-women-should-know-about-timing-treatment-and-survival","title":"Stage IV Breast Cancer During Pregnancy or After Childbirth: What Women Should Know About Timing, Treatment, and Survival","description":"\u003cp\u003eThis study examined 77 women with stage IV pregnancy-associated breast cancer (PABC), defined as breast cancer diagnosed during pregnancy or within one year after childbirth. Researchers found that the timing of diagnosis—whether during pregnancy or after delivery—did not affect treatment decisions or overall survival. However, women with triple negative tumors had strikingly poor outcomes, with a median survival of only 14 months and a 5-year survival rate of 0%, highlighting an urgent need for more research into this aggressive breast cancer subtype.\u003c\/p\u003e\n\n\u003ch1\u003eStage IV Breast Cancer During Pregnancy or After Childbirth: What Women Should Know About Timing, Treatment, and Survival\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#characteristics\"\u003ePatient and Tumor Characteristics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatments\"\u003eTreatments Women Received\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#survival\"\u003eSurvival Outcomes and Key Findings\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#obstetric\"\u003eObstetric and Fetal Outcomes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#context\"\u003ePutting the Findings in Context\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 77 women with stage IV pregnancy-associated breast cancer, survival was similar whether diagnosis occurred during pregnancy or within one year after delivery.\u003c\/li\u003e\n\u003cli\u003eAll 77 women received chemotherapy; breast surgery, endocrine therapy, and ovarian suppression were used commonly and similarly across pregnant and postpartum groups.\u003c\/li\u003e\n\u003cli\u003eAmong 17 women who continued pregnancy, including 9 who received chemotherapy, no fetal or obstetric complications were reported.\u003c\/li\u003e\n\u003cli\u003eDue to a small, single-center, mostly White retrospective sample, findings may not apply to all patients, and tests and treatments evolved over the 20-year study period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eBeing diagnosed with breast cancer is devastating at any age, but receiving this news during pregnancy or shortly after giving birth brings unique and overwhelming challenges. Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed either during pregnancy or within one year after delivery. It's a relatively rare condition, affecting approximately 17.5 to 39.9 women per 100,000 deliveries, yet breast cancer remains one of the most common cancers diagnosed during pregnancy.\u003c\/p\u003e\n\n\u003cp\u003eYoung women are particularly affected. Nearly 4% of women diagnosed with breast cancer before age 45 are pregnant or recently postpartum, and approximately 20% of those diagnosed between ages 25 and 29 are in this situation. Because most women of childbearing age don't routinely undergo breast cancer screening, they typically first notice a persistent breast lump. Unfortunately, the normal breast changes that occur during pregnancy and lactation can hide these lumps, making diagnosis more difficult and often delayed.\u003c\/p\u003e\n\n\u003cp\u003eThis delay matters. Studies have shown that women with PABC tend to have larger tumors, more lymph node involvement, and more aggressive cancer features compared to women whose breast cancer isn't associated with pregnancy. This can lead to a worse prognosis. There is also evidence suggesting that the natural breast tissue changes that occur after childbirth (called postpartum breast involution) may actually create an environment that promotes cancer growth and spread.\u003c\/p\u003e\n\n\u003cp\u003eStudying PABC is challenging for several reasons. There's no standard medical diagnostic code to identify these women in records, pregnancy information is often missing from cancer registries, and ethical restrictions prevent randomized clinical trials in pregnant women. Most of what we know comes from hospital-based studies and national cancer databases. But very little data exists specifically on women with stage IV (metastatic) PABC—cancer that has already spread to distant organs at the time of diagnosis or shortly thereafter. This study, from Memorial Sloan Kettering Cancer Center, is one of the first to focus exclusively on this rare and complicated situation.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eResearchers at Memorial Sloan Kettering Cancer Center conducted a retrospective review (a study looking back at medical records) of all women diagnosed with stage IV PABC between August 1, 1998, and November 5, 2018. PABC was defined as a breast cancer diagnosis during pregnancy or within one year after giving birth. The researchers also included women diagnosed with stage IV disease within one year of delivery, even if the initial breast cancer diagnosis occurred earlier, because pregnancy sometimes delayed the full staging evaluation.\u003c\/p\u003e\n\n\u003cp\u003eFrom an initial pool of 143 women, the researchers excluded those diagnosed with metastatic disease more than one year after delivery (14 women), those whose cancer spread more than one year after delivery (30 women), those without evidence of distant metastasis (21 women), and those with cancer in the opposite breast (1 woman). The final study group included 77 women.\u003c\/p\u003e\n\n\u003cp\u003eThe team collected detailed information on each woman's cancer characteristics, pregnancy history, treatments received, and outcomes. They compared women diagnosed with breast cancer during pregnancy to those diagnosed after delivery. The first site where the cancer spread was categorized as \"bone only\" or \"other\" (including organs such as the liver, lungs, or brain).\u003c\/p\u003e\n\n\u003cp\u003eFor statistical analysis, the researchers used standard tests to compare the two groups. Overall survival (OS)—the time from stage IV diagnosis to death or last follow-up—was calculated using the Kaplan-Meier method, a standard statistical approach. A p-value of less than 0.05 was considered statistically significant, meaning the finding is very unlikely to be due to chance (less than a 5% probability).\u003c\/p\u003e\n\n\u003ch2 id=\"characteristics\"\u003ePatient and Tumor Characteristics\u003c\/h2\u003e\n\n\u003cp\u003eThe 77 women in the study had a median age of 35 years at diagnosis (with the middle 50% of patients ranging from 32 to 37 years old). Of these, 26 women (34%) were diagnosed during pregnancy, and 51 women (66%) were diagnosed in the postpartum period. This makes the postpartum group about twice as large as the pregnancy group.\u003c\/p\u003e\n\n\u003cp\u003eAn important distinction was noted regarding how the stage IV disease was discovered. Overall, 66% of the women (51 out of 77) had \u003cstrong\u003ede novo stage IV breast cancer\u003c\/strong\u003e, meaning their cancer was already metastatic at the time of their initial breast cancer diagnosis. The remaining 34% (26 women) were initially diagnosed with earlier-stage breast cancer that then progressed to stage IV disease. Interestingly, women in the pregnancy group were significantly less likely to present with de novo stage IV cancer compared to the postpartum group (46% versus 76%; p = 0.01). This suggests that staging evaluations were sometimes deferred until after delivery in pregnant women.\u003c\/p\u003e\n\n\u003cp\u003eMost women (64%, or 49 out of 77) had their metastatic disease confirmed by biopsy. Another 35% (27 women) were diagnosed through imaging studies alone, and one woman (1.3%) had a brain tumor that was surgically removed. The location where the cancer first spread was similar between the pregnant and postpartum groups (p = 0.4).\u003c\/p\u003e\n\n\u003cp\u003eThe vast majority of women (95%, or 73 out of 77) had infiltrating ductal carcinoma, the most common type of breast cancer. The distribution of tumor subtypes was as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormone receptor (HR) positive, HER2 negative:\u003c\/strong\u003e 25 women (33%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHER2 positive:\u003c\/strong\u003e 35 women (45%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTriple negative (TN):\u003c\/strong\u003e 17 women (22%)—meaning the tumor lacks estrogen receptors, progesterone receptors, and HER2 amplification\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause the study spanned 20 years, HER2 testing practices evolved. Among the 17 women diagnosed between 1998 and 2007, 10 (59%) had HER2-positive tumors. In the later period (2008–2018), 24 of 60 women (40%) were HER2 positive. The postpartum group had a higher number of previous pregnancies (referred to as parity) than the pregnant group (p = 0.016), but otherwise the two groups were similar in their cancer characteristics.\u003c\/p\u003e\n\n\u003ch2 id=\"treatments\"\u003eTreatments Women Received\u003c\/h2\u003e\n\n\u003cp\u003eAll 77 women received some form of chemotherapy, including 9 women who received chemotherapy during pregnancy. This is a key finding—treatment was aggressive and consistent across both groups.\u003c\/p\u003e\n\n\u003cp\u003eSome form of breast surgery was performed in 43 women (56%). Of those, 19 women (44%) already had evidence of distant disease at the time of surgery. Among the 43 women with estrogen receptor (ER)-positive breast cancer, 37 (86%) received endocrine therapy (hormone-blocking treatment), and 27 (63%) were treated with ovarian suppression to reduce estrogen production.\u003c\/p\u003e\n\n\u003cp\u003eThe location of the first metastasis did not change treatment approach. Among 32 women whose first distant spread was to bone only, compared to 45 women whose first spread was to other organs (viscera), there was no difference in treatment received—including breast surgery (p = 0.5), chemotherapy (p \u0026gt; 0.9), or radiotherapy (p = 0.5).\u003c\/p\u003e\n\n\u003cp\u003eLooking specifically at the 52 women who developed bone metastasis (with or without involvement of other organs), 36% (17 women) received palliative radiotherapy in addition to chemotherapy, while 64% (30 women) were treated with systemic therapy alone. Treatment details were unknown for 5 women with bone metastasis. This shows that doctors tailored treatments to each patient's situation while maintaining consistent overall approaches.\u003c\/p\u003e\n\n\u003ch2 id=\"survival\"\u003eSurvival Outcomes and Key Findings\u003c\/h2\u003e\n\n\u003cp\u003eAfter a median follow-up of 31 months (ranging from 0 to 137 months), the overall 5-year survival rate for the entire group was \u003cstrong\u003e34%\u003c\/strong\u003e (95% confidence interval 21–46%). This means roughly one-third of women were alive 5 years after their stage IV diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eCritically, survival did not significantly differ between women diagnosed during pregnancy and those diagnosed postpartum (p = 0.2). The 5-year survival rates were 40% (95% CI 18–61%) for the pregnancy group and 31% (95% CI 17–46%) for the postpartum group. This is a reassuring finding—being pregnant at the time of diagnosis did not independently worsen survival.\u003c\/p\u003e\n\n\u003cp\u003eAt the end of the study period, 43 women (56%) had died from their disease, with a median time from diagnosis to death of 25 months (range 5–73 months). The tumor subtype dramatically influenced survival:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWomen with hormone receptor positive tumors (n = 24) had a median time to death of 37 months (range 9–73 months)\u003c\/li\u003e\n  \u003cli\u003eWomen with \u003cstrong\u003etriple negative tumors\u003c\/strong\u003e (n = 15) had a median time to death of just \u003cstrong\u003e14 months\u003c\/strong\u003e (range 5–39 months)\u003c\/li\u003e\n  \u003cli\u003eThe 5-year survival rate for women with triple negative tumors was \u003cstrong\u003e0%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe survival advantage for women with hormone receptor positive and HER2 positive tumors was statistically significant (p \u0026lt; 0.01). In fact, compared to women with triple negative tumors, the risk of death was reduced by:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e75%\u003c\/strong\u003e for women with HR positive\/HER2 negative tumors\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e for women with HR positive\/HER2 positive tumors\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e for women with HR negative\/HER2 positive tumors\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn other words, having any hormone receptor positivity or HER2 positivity was associated with a substantially better outlook compared to triple negative disease. Women who were alive with disease or showed no further evidence of stage IV disease at the end of the study were more likely to have HR positive and\/or HER2 positive tumors.\u003c\/p\u003e\n\n\u003cp\u003eWomen who were alive with disease or who had no further evidence of stage IV disease at last follow-up were more likely to have HR-positive and\/or HER2-positive tumors. This finding strongly emphasizes that triple negative PABC is an especially dangerous subtype.\u003c\/p\u003e\n\n\u003cp\u003eTo ensure the results were robust, researchers performed a sensitivity analysis—an additional statistical test—excluding the 9 women who had a therapeutic termination of pregnancy or spontaneous miscarriage. This was done to check whether ending the pregnancy (which might allow for fuller treatment options) affected outcomes. The results did not change, confirming that completing the pregnancy did not worsen survival.\u003c\/p\u003e\n\n\u003ch2 id=\"obstetric\"\u003eObstetric and Fetal Outcomes\u003c\/h2\u003e\n\n\u003cp\u003eAmong the 26 women diagnosed during pregnancy, 6 underwent therapeutic termination of pregnancy and 3 experienced a spontaneous miscarriage (miscarriage). The remaining 17 women continued their pregnancies and gave birth. Importantly, \u003cstrong\u003eno maternal complications related to pregnancy were reported\u003c\/strong\u003e in this group.\u003c\/p\u003e\n\n\u003cp\u003eDelivery outcomes were generally favorable. The majority of women (80%) delivered via cesarean section at a median of 37 weeks gestation (ranging from 32 to 41 weeks). Among the 13 women (76%) for whom information was available, \u003cstrong\u003eno fetal complications were reported\u003c\/strong\u003e. This included 9 women who received chemotherapy while pregnant—an important finding suggesting that chemotherapy can be safely administered during pregnancy with appropriate dosing and monitoring.\u003c\/p\u003e\n\n\u003ch2 id=\"context\"\u003ePutting the Findings in Context\u003c\/h2\u003e\n\n\u003cp\u003eRecent medical literature has reported improved survival for women with metastatic breast cancer overall, with median survival of 31 to 39 months, and 23 months for those with hormone receptor negative tumors. However, the women in this study with triple negative stage IV PABC fared far worse, with a median survival of only 14 months despite receiving aggressive multimodality treatment (combinations of surgery, chemotherapy, radiation, and targeted therapies).\u003c\/p\u003e\n\n\u003cp\u003eFor comparison, data from the Surveillance, Epidemiology, and End Results (SEER) national cancer database shows that the 5-year relative survival for women with distant (metastatic) triple negative breast cancer is 12.2%—yet in this PABC study, the 5-year survival for triple negative tumors was 0%. This highlights just how aggressive triple negative PABC can be.\u003c\/p\u003e\n\n\u003cp\u003eTriple negative breast cancer accounts for an estimated 12% to 17% of all breast cancers in women generally. However, it appears to be more common in pregnancy-associated cases. A retrospective study at Northwestern University found that HR-negative and triple negative breast cancers were most frequently diagnosed among women who were pregnant or within 2 years postpartum: 44.7% of tumors were HR-negative in the 0 to 2 year group versus 15.6% in the \u0026gt;2 to 5 year group, and 34.2% versus 11.5% for triple negative tumors, respectively. In the current study, 22% of the cohort had triple negative disease—higher than the general breast cancer population average.\u003c\/p\u003e\n\n\u003cp\u003eThe medical literature is mixed on whether pregnancy itself worsens breast cancer prognosis. Some studies have found no negative effect. For example, a multicenter study by Amant and colleagues compared 447 pregnant women to 865 nonpregnant women with stage I–III breast cancer and found similar overall survival after adjusting for other factors. Similarly, Iqbal and colleagues studied 7,553 women (501 with PABC) and found no significant difference in 5-year age-adjusted mortality (p = 0.2).\u003c\/p\u003e\n\n\u003cp\u003eHowever, other research paints a different picture. A meta-analysis of 30 studies found that PABC is independently associated with poorer survival, with a hazard ratio of 1.40 (95% CI 1.17–1.67) for overall survival compared to non-PABC. A more recent 2016 meta-analysis of 41 studies found an even stronger association, with a hazard ratio of 1.57 (95% CI 1.35–1.82). A retrospective study by Rodriguez and colleagues specifically examining stage IV disease found higher death rates among women with stage IV PABC versus stage IV non-PABC controls (89.7% versus 75.7%, respectively; p = 0.05).\u003c\/p\u003e\n\n\u003cp\u003eOne potential explanation for worse outcomes in PABC is delayed diagnosis. During pregnancy and lactation, increased estrogen and progesterone levels cause breast tissue to become more dense and enlarged, making physical exams and imaging more difficult. A study by Ishida and colleagues found that 192 women with PABC presented with significantly larger tumors and longer duration of symptoms compared to controls—an average of 6.3 months versus 5.4 months of symptoms before diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eThis delay is clearly visible in the current study. The median time from initial breast cancer diagnosis to stage IV diagnosis was \u003cstrong\u003e95 days in the pregnant group\u003c\/strong\u003e compared to just \u003cstrong\u003e15 days in the postpartum group\u003c\/strong\u003e—an 80-day difference. Forty-two postpartum women (82%) had their distant metastasis diagnosed within 3 months of their initial diagnosis, compared to only 13 pregnant women (50%). This likely reflects the practice of postponing staging scans until after delivery to avoid radiation exposure during pregnancy, rather than any difference in how quickly the cancer spread.\u003c\/p\u003e\n\n\u003cp\u003eEncouragingly, delayed treatment initiation doesn't appear to be common. A study by Beadle and colleagues, which assigned women to the pregnancy group if symptoms were noted during pregnancy, found improved overall survival among women who received any treatment during pregnancy compared to those whose treatment was delayed until after delivery (though this difference did not reach statistical significance: 78.7% versus 44.7%; p = 0.068). In the current study, women received aggressive and comparable treatment whether diagnosed during pregnancy or postpartum.\u003c\/p\u003e\n\n\u003cp\u003eAmong the 11 women who underwent mastectomy with known stage IV disease, the reasons varied: 7 had significant improvement in their distant metastases from neoadjuvant (pre-surgery) chemotherapy, 3 had rapid local disease progression requiring palliative surgery, and 1 developed a port-a-cath infection (a complication of the intravenous access device) while also noted to have a smaller breast mass.\u003c\/p\u003e\n\n\u003cp\u003eRegarding the safety of chemotherapy during pregnancy, a multicenter European study of 447 women with PABC found no difference in premature delivery rates between women with (n = 34) or without distant metastases. Infants exposed to chemotherapy during pregnancy had lower birth weights, but the authors suggested that pre-term delivery—not the chemotherapy itself—was the main factor affecting newborn health. The current study adds reassuring evidence: no fetal or obstetric complications were identified among the 17 women who completed pregnancy, including 9 who received chemotherapy while pregnant.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study carries several important messages for women facing stage IV PABC and their families:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTiming of diagnosis does not dictate outcomes.\u003c\/strong\u003e Whether a woman is diagnosed during pregnancy or within the year after giving birth, her survival prospects are essentially the same. Women should not feel that becoming pregnant or being pregnant caused a worse outcome.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCompleting the pregnancy is safe.\u003c\/strong\u003e The study found no obstetric or fetal complications among women who continued their pregnancy while receiving cancer treatment. Chemotherapy can be safely administered during pregnancy with appropriate dosing and monitoring.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor subtype matters enormously.\u003c\/strong\u003e Triple negative tumors—which lack estrogen receptors, progesterone receptors, and HER2 amplification—carry a particularly poor prognosis in stage IV PABC, with 0% surviving 5 years in this study. This is a critical area for future research, as these patients need better treatment options.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment should be aggressive regardless of pregnancy status.\u003c\/strong\u003e All women in this study received chemotherapy, and most received appropriate endocrine therapy and surgery. Pregnancy should not be a reason to withhold standard cancer treatments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultidisciplinary care is essential.\u003c\/strong\u003e The authors emphasize that beyond treating the cancer itself, women need psychological support, social work assistance for family needs (most women in the study had other children), reproductive specialist counseling for future family planning, and palliative care consultation as part of comprehensive, compassionate care.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eWhile this study provides valuable insights into a rare condition, it has important limitations that should be considered:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle institution, retrospective design:\u003c\/strong\u003e The study was conducted at one highly specialized cancer center and relied on reviewing past medical records, which carries a risk of selection bias.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited diversity:\u003c\/strong\u003e 88% of the women in the study identified their race as White, which may limit how well the findings apply to women of other racial and ethnic backgrounds.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall sample size:\u003c\/strong\u003e With only 77 women, the study is relatively small. However, this is largely unavoidable given how rare stage IV PABC is.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePossible undercount of miscarriages:\u003c\/strong\u003e Up to 20% of pregnancies may end in spontaneous abortion, but the low rate observed in this study (3 out of 26 pregnant women) may reflect referral bias or incomplete documentation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLong study period with evolving treatments:\u003c\/strong\u003e Treatment regimens changed substantially between 1998 and 2018, which could influence outcomes. However, the long follow-up period (up to 137 months) is also a strength, providing valuable long-term data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited obstetric detail:\u003c\/strong\u003e Because the cancer center doesn't have an obstetrics division, detailed obstetrical and fetal data were less granular than ideal.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research, here are practical steps for women who may be affected by pregnancy-associated breast cancer:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReport any persistent breast changes promptly.\u003c\/strong\u003e Because breast changes during pregnancy can hide lumps, any new lump, skin changes, or persistent discomfort should be evaluated by a doctor without delay. Delays in diagnosis can lead to more advanced disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about staging studies.\u003c\/strong\u003e If you're diagnosed with breast cancer during pregnancy, discuss with your oncology team whether staging scans can be safely performed during pregnancy or should be deferred until after delivery. Understanding the timing plan can help you feel more in control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek care at a multidisciplinary center.\u003c\/strong\u003e Ideally, your care should involve collaboration between breast surgeons, medical oncologists, radiation oncologists, maternal-fetal medicine specialists, and neonatologists who have experience with cancer during pregnancy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your tumor subtype.\u003c\/strong\u003e Ask your doctor about hormone receptor and HER2 status. Triple negative tumors require particularly aggressive treatment and close monitoring. Knowing your subtype helps you understand your treatment plan and prognosis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't delay treatment due to pregnancy.\u003c\/strong\u003e This study showed treatment was equally aggressive in pregnant and postpartum women, and completing pregnancy did not worsen outcomes. Work with your care team to establish a treatment timeline that is safe for both you and your baby.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuild your support network.\u003c\/strong\u003e Ask about mental health support, social work services, palliative care, and reproductive counseling. These services are not just for end-of-life care—they help manage symptoms, stress, and family needs throughout treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipate in research if possible.\u003c\/strong\u003e Given how little is known about stage IV PABC and the particularly poor outcomes seen with triple negative tumors, patient participation in registries and clinical trials is crucial for advancing understanding and treatment.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThis study is the first to focus exclusively on women with stage IV PABC, providing critical data to guide clinical care and future research. For women facing this difficult diagnosis, the key messages are: prompt multidisciplinary treatment matters, pregnancy timing doesn't change survival, and triple negative disease requires urgent research attention.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is pregnancy-associated breast cancer and how common is it?\u003c\/h3\u003e\n\u003cp\u003ePregnancy-associated breast cancer (PABC) is breast cancer diagnosed during pregnancy or within one year after childbirth. It is rare, affecting about 17.5 to 39.9 women per 100,000 deliveries, but breast cancer is one of the most common cancers in pregnancy. It can be harder to detect because normal pregnancy-related breast changes may hide lumps, sometimes delaying diagnosis.\u003c\/p\u003e\n\u003ch3\u003eDoes timing of diagnosis during pregnancy versus after delivery affect survival?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 77 women with stage IV pregnancy-associated breast cancer, survival did not differ significantly based on timing. The 5-year survival rate was 40% for women diagnosed during pregnancy and 31% for those diagnosed after delivery. Being pregnant at diagnosis did not independently worsen survival.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main limitations of this study on stage IV pregnancy-associated breast cancer?\u003c\/h3\u003e\n\u003cp\u003eThis was a single-center, retrospective study of 77 women, so it may have selection bias. Most women were White, which limits how broadly findings apply. The study spanned 20 years, during which treatments changed. Also, detailed obstetric and fetal information was limited because the cancer center did not have an obstetrics division.\u003c\/p\u003e\n\u003ch3\u003eWhat should women with pregnancy-associated breast cancer do based on these findings?\u003c\/h3\u003e\n\u003cp\u003eWomen should report any persistent breast change promptly, ask about staging scan timing, and confirm their tumor subtype because triple negative disease needs especially aggressive care. Treatment should not be delayed due to pregnancy. Seeking a multidisciplinary team and building a support network with social work, palliative care, and reproductive counseling is also recommended.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion for stage IV breast cancer diagnosed during pregnancy or within a year after giving birth?\u003c\/h3\u003e\n\u003cp\u003eSurvival is the same whether stage IV breast cancer is diagnosed during pregnancy or within the year after childbirth, so a second opinion should focus on confirming your tumor's receptor status and reviewing your treatment plan. Triple negative tumors carry an especially poor outlook, with a median survival of 14 months and no five-year survivors. Because treatment was equally aggressive in pregnant and postpartum women, a second opinion can help verify that your care includes standard chemotherapy, appropriate endocrine therapy, and coordination with maternal-fetal specialists. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated Breast Cancer (PABC)\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Regina Matar, MD; Angelena Crown, MD; Varadan Sevilimedu, MBBS, DrPH; Shari B. Goldfarb, MD; Mary L. Gemignani, MD, MPH\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Breast Surgery, Swedish Cancer Institute, Seattle, WA; Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; Breast Service, Department of Medicine, Memorial Sloan Kettering Cancer Center.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Annals of Surgical Oncology, March 2022, Volume 29, Issue 3, pages 1695–1702. doi:10.1245\/s10434-021-10901-6. Published in final edited form in 2022; author manuscript available in PMC March 2023. Presented in poster format at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care, March 18–19, 2021.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e This research was funded in part through the NIH\/NCI Cancer Center Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisclosures:\u003c\/strong\u003e Dr. Shari B. Goldfarb reports research funding from Sprout Pharmaceuticals and Paxman Coolers Ltd, and consulting\/medical advisory positions with Sermonix Pharmaceuticals, Procter and Gamble, NanOlogy LLC, and Ms. Medicine LLC. All other authors have no conflicts of interest to disclose.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in the Annals of Surgical Oncology. It is intended for educational purposes and does not replace individualized medical advice from your healthcare team. Always discuss your specific situation with your doctors.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47541990850716,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/stage-iv-breast-cancer-during-pregnancy-or-after-childbirth-what-women-should-know-about-timing-treatment-and-survival","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}